Sipuleucel-T immunotherapy for castration-resistant prostate cancer - PubMed (original) (raw)

Comment

. 2010 Nov 11;363(20):1966; author reply 1967-8.

doi: 10.1056/NEJMc1009982.

• PMID: 21067392
• DOI: 10.1056/NEJMc1009982

Comment

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Tetsuya Tanimoto et al. N Engl J Med. 2010.

No abstract available

PubMed Disclaimer

Comment on

• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Kantoff PW, et al. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. N Engl J Med. 2010. PMID: 20818862 Clinical Trial.

Similar articles

• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  Nabhan C. Nabhan C. N Engl J Med. 2010 Nov 11;363(20):1966-7; author reply 1968. doi: 10.1056/NEJMc1009982. N Engl J Med. 2010. PMID: 21067391 No abstract available.
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Kantoff PW, et al. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. N Engl J Med. 2010. PMID: 20818862 Clinical Trial.
• New treatments for metastic prostate cancer.
  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2010 Sep 6;52(1346):69-70. Med Lett Drugs Ther. 2010. PMID: 20814400
• Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
  Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN. Shore ND, et al. Cancer Control. 2013 Jan;20(1):7-16. doi: 10.1177/107327481302000103. Cancer Control. 2013. PMID: 23302902 Review.
• Sipuleucel-T for the treatment of advanced prostate cancer.
  Frohlich MW. Frohlich MW. Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004. Semin Oncol. 2012. PMID: 22595047 Review.

Cited by

• Prostate cancer-derived small extracellular vesicle proteins: the hope in diagnosis, prognosis, and therapeutics.
  Chen H, Pang B, Zhou C, Han M, Gong J, Li Y, Jiang J. Chen H, et al. J Nanobiotechnology. 2023 Dec 14;21(1):480. doi: 10.1186/s12951-023-02219-0. J Nanobiotechnology. 2023. PMID: 38093355 Free PMC article. Review.
• Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers.
  Li H, Sahu KK, Maughan BL. Li H, et al. Cancers (Basel). 2022 May 17;14(10):2460. doi: 10.3390/cancers14102460. Cancers (Basel). 2022. PMID: 35626064 Free PMC article. Review.
• Spherical nucleic acids: Organized nucleotide aggregates as versatile nanomedicine.
  Song Y, Song W, Lan X, Cai W, Jiang D. Song Y, et al. Aggregate (Hoboken). 2022 Feb;3(1):e120. doi: 10.1002/agt2.120. Epub 2021 Sep 14. Aggregate (Hoboken). 2022. PMID: 35386748 Free PMC article.
• Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma.
  García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. García-Sancha N, et al. Cancers (Basel). 2021 Oct 13;13(20):5134. doi: 10.3390/cancers13205134. Cancers (Basel). 2021. PMID: 34680282 Free PMC article. Review.
• Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
  Livas L, Hasani S, Kyprianou N. Livas L, et al. Adv Exp Med Biol. 2020;1296:183-198. doi: 10.1007/978-3-030-59038-3_11. Adv Exp Med Biol. 2020. PMID: 34185293

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information